CA2928287A1 - Forme solide d'axitinib - Google Patents

Forme solide d'axitinib Download PDF

Info

Publication number
CA2928287A1
CA2928287A1 CA2928287A CA2928287A CA2928287A1 CA 2928287 A1 CA2928287 A1 CA 2928287A1 CA 2928287 A CA2928287 A CA 2928287A CA 2928287 A CA2928287 A CA 2928287A CA 2928287 A1 CA2928287 A1 CA 2928287A1
Authority
CA
Canada
Prior art keywords
axitinib
polymorphic form
ethanol
peak
volumes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2928287A
Other languages
English (en)
Inventor
Evin Hazael Granados-Covarrubias
Jose Miguel Lazcano-Seres
Roberto Carlos Melgar-Fernandez
Armando ZAMBRANO-HUERTA
Martin Raul Montiel-Perez
Roberto Becerra-Ramirez
Blanca Lilia Saldana-Diaz
Israel Flores-Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signa SA de CV
Original Assignee
Signa SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signa SA de CV filed Critical Signa SA de CV
Publication of CA2928287A1 publication Critical patent/CA2928287A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2928287A 2015-04-28 2016-04-27 Forme solide d'axitinib Abandoned CA2928287A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562153754P 2015-04-28 2015-04-28
US62/153,754 2015-04-28

Publications (1)

Publication Number Publication Date
CA2928287A1 true CA2928287A1 (fr) 2016-10-28

Family

ID=57215556

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2928287A Abandoned CA2928287A1 (fr) 2015-04-28 2016-04-27 Forme solide d'axitinib

Country Status (1)

Country Link
CA (1) CA2928287A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111187253A (zh) * 2020-01-09 2020-05-22 鲁南制药集团股份有限公司 一种阿昔替尼新晶型
CN113943270A (zh) * 2020-07-15 2022-01-18 鲁南制药集团股份有限公司 一种阿昔替尼晶型
CN113943271A (zh) * 2020-07-15 2022-01-18 鲁南制药集团股份有限公司 一种阿昔替尼晶型及其制备方法
CN114685432A (zh) * 2020-12-28 2022-07-01 鲁南制药集团股份有限公司 阿昔替尼盐晶型及其制备方法
CN114685437A (zh) * 2020-12-25 2022-07-01 鲁南制药集团股份有限公司 阿昔替尼与糖精共晶
CN114685435A (zh) * 2020-12-28 2022-07-01 鲁南制药集团股份有限公司 阿昔替尼马来酸盐晶型及其制备
CN114685431A (zh) * 2020-12-26 2022-07-01 鲁南制药集团股份有限公司 一种阿昔替尼柠檬酸盐晶型
CN114685433A (zh) * 2020-12-28 2022-07-01 鲁南制药集团股份有限公司 一种阿昔替尼香草酸共晶盐及其制备

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111187253B (zh) * 2020-01-09 2023-05-09 鲁南制药集团股份有限公司 一种阿昔替尼新晶型
CN111187253A (zh) * 2020-01-09 2020-05-22 鲁南制药集团股份有限公司 一种阿昔替尼新晶型
CN113943270A (zh) * 2020-07-15 2022-01-18 鲁南制药集团股份有限公司 一种阿昔替尼晶型
CN113943271A (zh) * 2020-07-15 2022-01-18 鲁南制药集团股份有限公司 一种阿昔替尼晶型及其制备方法
CN113943271B (zh) * 2020-07-15 2023-11-14 鲁南制药集团股份有限公司 一种阿昔替尼晶型及其制备方法
CN113943270B (zh) * 2020-07-15 2023-05-09 鲁南制药集团股份有限公司 一种阿昔替尼晶型
CN114685437A (zh) * 2020-12-25 2022-07-01 鲁南制药集团股份有限公司 阿昔替尼与糖精共晶
CN114685437B (zh) * 2020-12-25 2022-12-09 鲁南制药集团股份有限公司 阿昔替尼与糖精共晶
CN114685431B (zh) * 2020-12-26 2022-11-29 鲁南制药集团股份有限公司 一种阿昔替尼柠檬酸盐晶型
CN114685431A (zh) * 2020-12-26 2022-07-01 鲁南制药集团股份有限公司 一种阿昔替尼柠檬酸盐晶型
CN114685433B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 一种阿昔替尼香草酸共晶盐及其制备
CN114685432B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 阿昔替尼盐晶型及其制备方法
CN114685435B (zh) * 2020-12-28 2023-01-31 鲁南制药集团股份有限公司 阿昔替尼马来酸盐晶型及其制备
CN114685433A (zh) * 2020-12-28 2022-07-01 鲁南制药集团股份有限公司 一种阿昔替尼香草酸共晶盐及其制备
CN114685435A (zh) * 2020-12-28 2022-07-01 鲁南制药集团股份有限公司 阿昔替尼马来酸盐晶型及其制备
CN114685432A (zh) * 2020-12-28 2022-07-01 鲁南制药集团股份有限公司 阿昔替尼盐晶型及其制备方法

Similar Documents

Publication Publication Date Title
CA2928287A1 (fr) Forme solide d'axitinib
US10246418B2 (en) Crystal form of lenvatinib methanesulfonate salt and preparation method thereof
WO2017008773A1 (fr) Formes cristallines d'acide obéticholique
AU2013332205B2 (en) Solid forms of Nilotinib hydrochloride
JP5899214B2 (ja) ４−［−２−［［５−メチル−１−（２−ナフタレニル）−１ｈ−ピラゾール−３−イル］オキシ］エチル］モルホリン塩酸塩の固体形態
US9725454B2 (en) Crystalline forms of ponatinib hydrochloride
WO2017140283A1 (fr) Solvates d'olaparib cristallin avec l'acétone, le 2-propanol et/ou la méthyléthylcétone
EP3256474A1 (fr) Sel de sulfate ibrutinib
WO2016127963A1 (fr) Formes solides de sels de palbociclib
WO2018046028A1 (fr) Formes à l'état solide d'éluxadoline
CZ2014773A3 (cs) Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu
WO2015090259A1 (fr) Procédé de préparation de forme n-6 polymorphe anhydre de dasatinib
CZ2016705A3 (cs) Krystalické formy 2- [1-ethylsulfonyl-3- [4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) pyrazol-1-yl] azetidin-3-yl] acetonitrilových solí a jejich příprava
US20220098206A1 (en) Solid state forms of oclacitinib maleate
WO2016157136A1 (fr) Formes cristallines de l'idélalisib
WO2017016529A1 (fr) Formes solides de ceritinib base libre
CN108026087A (zh) (4-((3r,4r)-3-甲氧基四氢-吡喃-4-基氨基)哌啶-1-基)(5-甲基-6-(((2r,6s)-6-(对-甲苯基)四氢-2h-吡喃-2-基)甲基氨基)嘧啶-4-基)甲酮柠檬酸盐
CA2964198C (fr) Formes solides du chlorhydrate de nilotinib
US20220363682A1 (en) Novel salts and crystals
US10532981B2 (en) Crystalline modifications of methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylate salts and methods of preparation thereof
CA2944150A1 (fr) Formes polymorphes et co-cristaux d'un inhibiteur de c-met
WO2016113242A1 (fr) Di-pidotimod benzathine et ses formes solides
CZ2015743A3 (cs) Pevné formy volné báze ceritinibu
CZ2015641A3 (cs) Soli ceritinibu
CZ2015366A3 (cs) Pevné formy Daclatasviru

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20190429